Background: Pre-eclampsia carries high risk for pregnant women and their babies to develop a wide range of adverse outcomes. Unfortunately, some medications used in its management causes serious side effects if they were not monitored properly. Magnesium sulphte, being widely used in controlling and preventing convulsions in cases of severe pre-eclampsia, should be utilized cautiously by monitoring of its serum levels.
Objective: The aim of this study was to correlate between cord blood and maternal serum magnesium levels in pre-eclamptic women received magnesium sulphate before delivery. Patients and Methods: Cohort study on 36 pregnant women, more than 28 weeks’ gestation, with the diagnosis of pre-eclampsia, who received magnesium sulphate (MgSO4), were recruited. Blood samples obtained from both maternal serum and cord blood was collected instantly at the time of delivery for detection of magnesium as well as calcium levels.
Results: 94.5% were diagnosed with pre-eclampsia, while the rest had HELLP syndrome. The treated women received total mean MgSO4 of 14.4±6.0 grams during a mean duration of 5.1±3.3 hours. Mean±SD of maternal and cord magnesium levels were (2.2±0.4mmol/L) and (1.8±0.3mmol/L), respectively. Significant positive correlation (P |
